Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The Role of Inspiratory Muscle Training in Sickle Cell Anemia Related Pulmonary Damage due to Recurrent Acute Chest Syndrome Attacks
source: Case Reports in Hematology
year: 2015
authors: Camcıoğlu B, Boşnak-Güçlü M, Karadallı MN, Akı ŞZ, Türköz-Sucak G
summary/abstract:Background:
The sickling of red blood cells causes a constellation of musculoskeletal, cardiovascular, and pulmonary manifestations. A 32-year-old gentleman with sickle cell anemia (SCA) had been suffering from recurrent acute chest syndrome (ACS). Aim. To examine the effects of inspiratory muscle training (IMT) on pulmonary functions, respiratory and peripheral muscle strength, functional exercise capacity, and quality of life in this patient with SCA.
Methods:
Functional exercise capacity was evaluated using six-minute walk test, respiratory muscle strength using mouth pressure device, hand grip strength using hand-held dynamometer, pain using Visual Analogue Scale, fatigue using Fatigue Severity Scale, dyspnea using Modified Medical Research Council Scale, and health related quality of life using European Organization for Research and Treatment of Cancer QOL measurement.
Results:
A significant improvement has been demonstrated in respiratory muscle strength, functional exercise capacity, pain, fatigue, dyspnea, and quality of life. There was no admission to emergency department due to acute chest syndrome in the following 12 months after commencing regular erythrocytapheresis.
Conclusion:
This is the first report demonstrating the beneficial effects of inspiratory muscle training on functional exercise capacity, respiratory muscle strength, pain, fatigue, dyspnea, and quality of life in a patient with recurrent ACS.
DOI: 10.1155/2015/780159
read more full text
+myBinderRelated Content
-
Brandon Hardesty, MDBrandon Hardesty serves as an IHTC adult...
-
Vaso-Occlusive Crises and Costs of Sickle Cell Disease in Patients With Commercial, Medicaid and Medicare Insurance ...Aim: To characterize vaso-occlusive cri...
-
Comparative Cost Analysis of Therapy in Sickle Cell Anemia: Supportive Care Vs. Bone Marrow TransplantObjective: A comparative cost analysis o...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
New treatment plan leads to better pain control for acute sickle cell crisisThere’s new hope for the 70,000 to 80,...
-
Magical Monday Motivation: Sickle Cell Warrior # 17Living with Sickle Cell disease requires...
-
University of Pittsburgh School of MedicineThe University of Pittsburgh School of M...
Don’t forget to join the oneSCDvoice community!
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.
